Retrospective immunohistochemistry analysis of 164 EGFR-mutant and 159 EGFR wild-type tumors revealed that the expression of CD3, CD4, and Foxp3 was significantly higher in EGFR-mutant NSCLC tumors than that in the EGFR wild-type NSCLC tumors [120]. The gene discussed is EGFR; the disease is non-small cell lung carcinoma.